Lakefront Biotherapeutics (GLPGF) Net Income Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Net Income Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | -129.59% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | 116.82% |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -333.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -333.24% |
| Mar 31, 2026 | -11.26% |
| Dec 31, 2025 | 1,041.95% |
| Sep 30, 2025 | -150.36% |
| Jun 30, 2025 | 61.14% |
| Mar 31, 2025 | -146.20% |
| Dec 31, 2024 | 768.72% |
| Sep 30, 2024 | 16.28% |
| Jun 30, 2024 | 39.92% |
| Mar 31, 2024 | 102.05% |
| Dec 31, 2023 | 167.15% |
| Sep 30, 2023 | 42.95% |
| Jun 30, 2023 | -86.15% |
| Mar 31, 2023 | 34.60% |
| Dec 31, 2022 | -26.06% |
| Sep 30, 2022 | -28.10% |
| Jun 30, 2022 | -35.66% |
| Mar 31, 2022 | 41.51% |
| Dec 31, 2021 | -52.35% |
| Sep 30, 2021 | -14.72% |